BioCryst Launches Orladeyo (berotralstat) in Spain
BioCryst Pharmaceuticals Inc today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted marketing authorization for oral, once-daily Orladeyo (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older.
“We have an experienced and motivated team in Spain that is enthusiastic about the impact the availability of the first oral, once daily therapy can have for people with HAE in Spain,” said Charlie Gayer, chief commercial officer of BioCryst. “Spanish patients and physicians have shared with us the need to expand treatment options and we are excited now to be in a position to support access to those who can benefit most.”
(Source: BioCryst)
